Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 449Carcinoma, Non-Small-Cell Lung 372Neoplasms 349Prostatic Neoplasms 285Colorectal Neoplasms 273Multiple Myeloma 211Lung Neoplasms 201Neoplasm Metastasis 185Leukemia, Myeloid, Acute 163Ovarian Neoplasms 159Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 140Melanoma 131Recurrence 108Glioblastoma 105Head and Neck Neoplasms 103Carcinoma, Renal Cell 103Endometrial Neoplasms 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Lymphoma, Non-Hodgkin 95Stomach Neoplasms 94Carcinoma, Hepatocellular 94Lymphoma 93Triple Negative Breast Neoplasms 92Brain Neoplasms 90Uterine Cervical Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Glioma 79Urinary Bladder Neoplasms 78Sarcoma 78

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Oligoprogressive × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡